Delving into the Latest Updates on ValenTx, Inc. with Synapse

Overview

To evaluate the safety and efficacy of the endoscopically implanted ValenTx EndoPass™ System for treatment of adults with severe obesity.
The EndoPass System is indicated for weight loss in adults with a body mass index (BMI) ≥35 and ≤ 50 kg/m2 who have failed more conservative weight loss methods.

Start Date01 Mar 2016

Sponsor / Collaborator

ValenTx, Inc.

NCT02954003

/ Unknown statusNot Applicable

An Open Label Trial of the Safety and Effectiveness of the ValenTx Endo Bypass System and Use of the Endoscopic Anchor Placement Device in Obese Subjects

The purpose of this study is to collect clinical data to support the use of the ValenTx Endo Bypass System to improve weight loss and the resolution of comorbidities in obese subjects.

Start Date01 Dec 2013

Sponsor / Collaborator

ValenTx, Inc.

NCT01207830

/ CompletedNot Applicable

A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Subjects

The purpose of this study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese subjects

Start Date01 Mar 2010

Sponsor / Collaborator

ValenTx, Inc.

100 Clinical Results associated with ValenTx, Inc.

Login to view more data

0 Patents (Medical) associated with ValenTx, Inc.

Login to view more data

100 Deals associated with ValenTx, Inc.

Login to view more data

100 Translational Medicine associated with ValenTx, Inc.

Login to view more data